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Biomarkers of Targeted Therapy and Immuno-Oncology in
Cancers Metastatic to the Breast
Semir Vranic, MD, PhD,* Wijendra Senarathne, MD,† Phillip Stafford, PhD,†
Kelsey Poorman, PhD,† Barbara A. Pockaj, MD,‡ and Zoran Gatalica, MD, DSc‡
Abstract: The breast is a rare site for metastases, and their mo-
lecular characteristics have not been studied yet. Intrinsic mo-
lecular genetics, cancer characteristics, and breast tissue immune
responses in diverse metastases to the breast have not been pre-
viously studied. We identified 64 patients with cancers metastatic
to the breast: 51 carcinomas and 13 melanomas. Programmed
death ligand 1 (PD-L1), steroid receptors, and HER2/neu ex-
pressions were evaluated using immunohistochemistry. Gene
sequencing, copy number alterations, microsatellite instability,
and tumor mutational burden were performed using next-
generation sequencing platforms. The 3 most common primary
sites for metastatic carcinomas were lung (37%), ovary (29%),
and fallopian tubes/peritoneum (14%). TP53 mutations were
commonly (50%) observed among the carcinoma cases, while
other mutations were characteristic for the primary cancers
(VHL in renal, BRCA1 in the fallopian tube, and BRAF in
melanomas). High tumor mutational burden was detected in 5/14
carcinomas and 3/7 melanomas. Tumor cell PD-L1 expression
was detected in 6 carcinomas, but not in any of the melanomas,
whereas immune cells’ expression of PD-L1 was seen in 17 car-
cinomas and 6 melanomas. Estrogen receptor status was positive
in 13/49 carcinomas including 12 adenocarcinomas originating
from the ovary and fallopian tube or peritoneum and 1 duodenal
neuroendocrine carcinoma. No carcinoma was HER2/neu pos-
itive. Intrinsic genetic characteristics of the metastases to the
breast followed the pattern commonly seen in primary tumors.
Biomarkers of potential benefit to immune checkpoint inhibition
therapy were limited to PD-L1-positive non–small cell lung
cancer. No common characteristics of the heterogeneous group
of tumor metastases to this organ were identified.
Key Words: breast, secondary cancers, metastasis, carcinoma,
molecular profiling, immuno-oncology
(Appl Immunohistochem Mol Morphol 2019;00:000–000)
Metastatic cancers to the breast are rare and constitute1% to 2% of all breast malignancies.1 When hema-
tologic neoplasms are excluded, the frequency of second-
ary cancer deposits in the breast is ∼1%.1 Intramammary
metastases are rarely isolated and are typically seen con-
currently with metastases to other anatomic sites.1,2
A comprehensive review by Koch et al3 revealed that
melanomas are the most common secondary neoplasms in
the breast (∼30%) followed by lung, gynecologic, gastro-
intestinal, and hematologic malignancies.
Comprehensive molecular profiling has become the
cornerstone of precision medicine. Apart from the cancers
of unknown primary (CUP), most available molecular
profiling information that pertains to the targeted cancer
treatment originates from the primary tumors.4 A recently
published study by Robinson et al4 revealed that the most
commonly mutated genes in metastatic cancers were
TP53, CDKN2A, PTEN, PIK3CA, and RB1. The study
also revealed a significant burden of pathogenic germline
variants (12.2% of all tested cases of which 75% were re-
lated to DNA repair defects).4 A study of Kim et al5
performed on 66 metastatic breast cancer samples using
whole-exome, RNA-Seq, and targeted deep sequencing
uncovered TP53 and PIK3CA as the most frequent mo-
lecular events in breast metastases. A study by Ng et al6
focusing on synchronous primary breast cancers and their
corresponding metastases confirmed a similar mutational
portrait. However, metastatic breast cancers were enriched
in several unique mutational alterations in genes involved
in epithelial-to-mesenchymal transition [eg, SMAD4,
TCF7L2, and TCF4 (ITF2)].
Given their rarity, the molecular characteristics of
secondary (metastatic) cancers to the breast and their po-
tential impact on therapy decisions are completely unknown.
Our comprehensive literature search (all identified studies are
summarized in Supplemental Table 1, Supplemental Digital
Content 1, http://links.lww.com/AIMM/A243) revealed
no study that specifically explored molecular features of
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secondary cancers to the breast. In the present study, we
reviewed the largest cohort of cancers metastatic to the
breast profiled at a single reference center (Caris Life Sci-
ences, Phoenix, AZ) for intrinsic cancer characteristics and
biomarkers of immuno-oncologic (I-O) therapies.
MATERIALS AND METHODS
Samples
Cases of metastatic (secondary) cancers to the breast
submitted for molecular profiling at Caris Life Sciences
between July 2012 and August 2017 were analyzed. The
histologic diagnoses including review of the diagnostic
immunohistochemical workup performed at the referring
pathology laboratories were confirmed in all cases by a
board-certified pathologist at Caris Life Sciences. Hema-
tologic malignancies and sarcomas, and melanomas and
other cancers affecting the skin of the breast were excluded
from the study.
Caris Life Sciences deidentified all the reports
and remnant samples provided by the referring labo-
ratories. Given that the remnant tissues from previous
samplings with no associated identifiers were used, this
research was compliant with 45 CFR 46.101(b). There-
fore, the present study was deemed exempt from institu-
tional review board approval, and consent requirements
were waived.
Next-generation Sequencing (NGS)
Specimens were profiled using 2 massively parallel
NGS (44-gene panel utilizes TruSeq Amplicon panel tar-
geting mutation hotspots in 45 genes; 592-gene panel uti-
lizes SureSelect XT biotinylated RNA probes to capture
DNA fragments from the exons of 592 genes (Agilent,
Santa Clara, CA), reflecting their availability at the time
of testing (Table 1). Sequencing of the 44-gene panel used
the MiSeq instrument, and, for the 592-gene panel, the
NextSeq instrument was used (Illumina, San Diego,
CA).7–9
Copy number alterations (CNAs) were also explored
on samples profiled with the 592-gene NGS panel. CNAs
were calculated by comparing the depth of sequencing of
genomic loci with a diploid control and the known per-
formance of these genomic loci. Gains ≥ 6 copies were
considered amplified.7,10
The tumor mutational burden (TMB) was calculated
by counting nonsynonymous missense mutations and ex-
cluding common germline variants using dbSNP 137 and
1000 genomes. TMB was considered high if ≥ 10 muta-
tions/Mbp were detected, for any cancer type. TMB values
were also used to compute a percentile per cancer type.
For each of the metastatic cancers to the breast (non–
small cell lung cancer [NSCLC], small cell lung cancer,
melanoma, ovarian carcinoma, bladder carcinoma, breast
carcinoma, and CUP), the total number of patients with a
certain TMB score was divided by the total number of
patients for that cancer cohort, resulting in a percentile
score. Table 2 and Figure 1 list the percentiles for 10
representative TMB values, allowing for interconversion
between TMB score and percentile. Table 3 lists
metastatic cancers’ TMB when determined to be “TMB
High” with corresponding percentiles relative to
TMB= 10 displayed.
Microsatellite instability (MSI) was calculated from
the NGS data by direct analysis of short tandem repeat
tracts in the target regions of sequenced genes. The count
only included alterations that resulted in increases or de-
creases in the number of repeats; high MSI was defined as
≥ 46 altered microsatellite loci. This threshold was estab-
lished by comparing NGS with the polymerase chain
reaction–based microsatellite fragment analysis results
from ∼2100 samples.7,8,11
Immunohistochemistry (IHC)
All IHC stains were performed using automated
platforms (Benchmark; Ventana Medical Systems and
DAKO Autostainer; Agilent, Santa Clara, CA) at a
CLIA/CAP/ISO15189/NYSDOH certified clinical labo-
ratory (Caris Life Sciences). Ki-67 (MIB1 antibody) was
used to assess the proliferation rate of the neuroendocrine
neoplasms (lung and duodenum).
Programmed death ligand 1 (PD-L1) expression was
evaluated in the tumor cells (TCs) using SP142 (Ventana;
n= 41), 28-8 (Agilent DAKO; for melanoma cases n= 13),
and 22c3 clones (Agilent pharmDX DAKO, for NSCLC
cases, n= 10) (Table 1). Specimens were considered
positive using the SP142 PD-L1 clone if ≥ 5% of TCs
exhibited circumferential membranous positivity.12–14 The
22c3 positivity in NSCLC was based on established
companion diagnostic criteria (Agilent). 28-8 PD-L1
positivity in melanomas was assessed using established
complementary diagnostic criteria (> 1% viable positive
cells) for nivolumab treatment in melanoma. We also
assessed PD-L1 expression in immune cells (ICs)
comprising lymphocytes, macrophages, and dendritic
TABLE 1. Overview of the Molecular Assays Used For Profiling
of Metastatic Cancers to the Breast
Assay No. Tested Cases
CNA 17
MSI 19
TMB 19
44-gene panel (TruSeq Amplicon panel) 41
592-gene panel (NGS) 19
Immunohistochemistry
PD-L1 64
SP142 clone 41
28-8 clone (melanoma) 13
22c3 clone (NSCLC) 10
Steroid receptors (ER, PR, and AR) 49 (only carcinomas)
HER2/neu 45 (only carcinomas)
Ki-67 10 (only neuroendocrine
neoplasms)
AR indicates androgen receptor; CNA, copy number alteration; ER, estrogen
receptor; HER2, human epidermal growth factor receptor 2; MSI, microsatellite
instability; NGS, next-generation sequencing; NSCLC, non–small cell lung cancer;
PR, progesterone receptor; TMB, tumor mutational burden.
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cells. Placental tissue served as a positive control for all
PD-L1 antibodies.7
Androgen receptor (AR; Leica Biosystems), estrogen
receptor (ER; Ventana), and progesterone receptor (PR;
Ventana) were explored using a ≥ 1% threshold for nu-
clear positivity for ER and PR15 and 10% for AR.10 Only
for ovarian/fallopian tube and peritoneal carcinomas, we
used the 3+/50% or 2+/75% threshold for ER positivity.
Human epidermal growth factor receptor 2 (HER2;
Ventana) was considered positive if > 10% cancer cells
showed complete, circumferential (3+) expression.16
RESULTS
Clinicopathologic Characteristics of the Cohort
We found 64 patients with cancers metastatic to the
breast: 51 metastatic carcinomas and 13 melanomas
among 4500 breast biopsy specimens that were profiled in
the period 2012 to 2017 (frequency ∼1.4%) (Table 3).
There were 49 female and 2 male patients (both metastatic
renal carcinomas) with a mean age of 57 years (range, 20
to 90 y). The known primary sites of metastatic
carcinomas included the following (and they are): lung
(n= 19, 30%), ovary (n= 15, 23%), peritoneum/fallopian
tube (n= 7, 11%), kidney (n= 4, 6%), bladder (n= 2, 3%),
and duodenum and colon (n= 1 each). CUPs were rare
(n= 2).
Histologically, 28 of the metastatic carcinomas were
adenocarcinomas. Ten cases were neuroendocrine carci-
nomas (NEC) including 9 from the lung (7 small cell
carcinomas (average Ki-67: 55%), 1 large NEC (Ki-67:
90%), 1 atypical carcinoid (Ki-67: 10%), and 1 duodenal
NEC (Ki-67: 22%). Two cases were squamous cell
carcinomas (both from the lung). Histopathologic evalu-
ation of the 2 CUPs showed squamous carcinoma in 1
and serous-type adenocarcinoma in the other. The
remaining 11 cases were of undifferentiated/other types of
carcinoma.
Thirteen metastatic melanomas to the breast were
encountered in 10 female and 3 male patients (mean age:
54 y, range, 22 to 90 y). Nine cases had no reported/known
primary site (melanoma of unknown primary/MUP),17
while the remaining 4 metastatic melanomas originated
from the skin of the head and neck, trunk, and buttock.
Steroid Receptor Profile and HER2 Status in
Metastatic Carcinomas
ER was positive in 13/49 tested cases. A vast ma-
jority of the ER-positive cases originated from the ovary,
fallopian tubes, and/or peritoneum (12 cases); the re-
maining ER-positive case was metastatic duodenal NEC.
PR positivity was observed in 5 cases, originating from the
ovary, fallopian tubes, and peritoneum. AR was positive
in only 3 cases including 2 ovarian and 1 renal cell car-
cinoma. None of the tested cases (n= 45) exhibited HER2
positivity. Both CUP cases were negative for all 3 steroid
receptors and HER2. None of the cases harbored muta-
tions in the estrogen receptor gene (ESR1) or the ERBB2
(HER2) gene.
TABLE 2. TMB Conversion Table to Percentiles
TMB Breast NSCLC SCLC Melanoma Ovarian Bladder CUP
3 0.02 0.01 0.01 0.01 0.02 0.01 0.02
5 0.17 0.07 0.05 0.07 0.2 0.05 0.15
7 0.47 0.23 0.17 0.21 0.55 0.23 0.42
9 0.65 0.36 0.29 0.29 0.74 0.37 0.57
11 0.83 0.54 0.5 0.41 0.91 0.55 0.72
13 0.91 0.68 0.69 0.48 0.96 0.69 0.8
15 0.95 0.78 0.82 0.56 0.98 0.76 0.84
17 0.96 0.85 0.91 0.62 0.98 0.83 0.86
20 0.97 0.9 0.96 0.68 0.99 0.89 0.89
22 0.98 0.93 0.97 0.71 0.99 0.91 0.91
24 0.98 0.94 0.98 0.74 0.99 0.93 0.92
26 0.99 0.95 0.98 0.76 0.99 0.95 0.93
CUP indicates cancer of unknown primary; NSCLC, non–small cell lung carcinoma; SCLC, small cell lung carcinoma; TMB, tumor mutational burden.
FIGURE 1. Plot of tumor mutational burden (TMB) (x-axis)
versus percentile (y-axis) for cancer types in Table 2. Black dots
represent breast carcinoma; red line represents non–small cell
lung cancer; green line represents small cell lung cancer; blue
line represents melanoma; cyan line represents ovarian cancer;
magenta line is bladder cancer.
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I-O Biomarkers in Metastatic Carcinomas
PD-L1 Status
PD-L1 expression on TCs was present in n= 6/51
cases (12%). PD-L1 TC-positive cases included 4 NSCLC
(2 adenocarcinomas, 1 squamous cell carcinoma, and 1
NSCLC not otherwise specified, respectively), 1 bladder
carcinoma, and 1 CUP case with squamous differ-
entiation. Of note, 2 cases (lung adenocarcinoma and a
CUP with squamous differentiation) exhibited high PD-
L1 positivity (80% positivity).
The expression of PD-L1 in ICs was observed in
n= 17/51 cases. The positive cases included metastatic lung
(n=7, 3 of which were NEC), peritoneal (n= 3), bladder,
ovarian and fallopian tube (n= 2 each), and colorectal
carcinoma (n= 1). Only 3 cases demonstrated moderate to
strong IC PD-L1 expression (30% to 50% positive ICs) (1
case each of bladder, ovarian, and fallopian tube carcino-
ma). Of note, 3 cases (2 NSCLC and 1 bladder carcinoma)
had PD-L1 positivity in both cancer and ICs. None of the
CUP cases had PD-L1 expression in ICs.
TMB and MSI Status in Metastatic Carcinomas and
Primary Breast Cancers
TMB results were available for n= 14 metastatic
carcinomas; the average TMB was 9.6 mutations/Mbp.
High TMB was observed in 5 cases: three lung carcino-
mas, 1 ovarian, and 1 CUP case (Table 3). The highest
TMB was observed in the CUP case with squamous
differentiation (29 mutations/Mbp). This case also
exhibited a diffuse (80%) PD-L1 expression.
MSI status was available for n= 14 metastatic car-
cinomas; all were microsatellite stable.
Mutational Profile and CNAs of Metastatic
Carcinomas
The mutational profile of the cohort is summarized
in Table 4. TP53 mutation was the most common (50%)
across all the histologies and lineages. Four cases with
KRASmutations were observed: Two mutations were seen
in NSCLCs, 1 in peritoneal adenocarcinoma and in 1
CUP case (adenocarcinoma), respectively. Similarly, 4
lung-primary cases had RB1 gene mutations (2 small cell
lung cancer, 1 squamous, and 1 not otherwise specified,
respectively). Three loss-of-function mutations in PTEN
were detected (2 lung neuroendocrine and 1 lung
adenocarcinoma). One case each of lung and ovarian
adenocarcinoma carried pathogenic BRAF gene
mutations. Similarly, 2 NRAS gene mutations were
detected in 1 ovarian and colorectal adenocarcinoma,
respectively. Two PIK3CA gene mutations were present in
1 renal and bladder carcinoma case. The first CUP
presented with squamous differentiation harbored
mutations in TP53, KDM6A, and TSC2 genes along
with the amplification of the NFIB gene. The second CUP
case (adenocarcinoma histology) harbored mutations in
both KRAS and STK11 genes.
Some of the detected mutations were lineage-char-
acteristic: 2 VHL mutations in renal clear cell carcinomas
and 1 SMARCB1 mutation in a renal medullary carci-
noma case; one BRCA1 mutation was detected in a fal-
lopian tube carcinoma. The remaining ovarian and
peritoneal carcinomas (n= 7) did not have BRCA muta-
tions. Neuroendocrine lung carcinomas (n= 8) harbored
TP53 and RB1 gene mutations (n= 2 each). Other muta-
tions (AKT1, APC, ARID1A, ARID2, FANCC, FBXW7,
TABLE 3. A Summary of the Obtained Results For Predictive Immuno-oncologic Biomarkers in Metastatic Cancers to the Breast
Histologic Subtype PD-L1 (TC) PD-L1 (IC) High TMB Status* H-MSI Status†
Carcinomas, n/N (%) 6/51 (12) 17/51 (33) 5/14 (36) 0/14 (0)
Lung carcinoma 4/19 7/19 3/7 0/7
NSCLC 4/10 4/10 2/4 (50th percentile) 0/4
SCLC 0/9 3/9 1/3 (50th percentile) 0/3
Ovarian carcinoma 0/15 2/15 1/4 (87th percentile) 0/4
Fallopian tube/peritoneum 0/7 5/7 0/1 0/1
Kidney carcinoma 0/4 0/4 NA NA
RCC 0/3 0/3 NA NA
Medullary carcinoma 0/1 0/1 NA NA
Bladder carcinoma 1/2 2/2 NA NA
Duodenal NEC 0/1 0/1 0/1 (55th percentile) 0/1
Colorectal carcinoma 0/1 1/1 NA NA
CUP 1/2 0/2 1/1 0/1
Melanomas, n/N (%) 0/13 (0) 6/12 (50)‡ 3/7 (43) 0/5 (0)
MUP 0/9 (0) 5/9 2/4 0/2
Cutaneous melanoma 0/4 1/3 1/3 (38th percentile) 0/3
Far left: TMB as a numeric value is listed, followed by the resulting percentile per cancer type. For computing percentile, a cohort of patients was used. For NSCLC,
11,699 patients; for SCLC, 610 patients; for melanoma, 1751 patients; for ovarian cancer, 8234; for bladder cancer, 1016 nonurothelial patients, and for CUP, 1571 patients.
*TMB was considered high if ≥ 10 mutations/Mbp were detected.
†H-MSI status was defined as ≥ 46 altered microsatellite loci.
‡One case was difficult to assess for PD-L1 expression in inflammatory cells due to the heavy pigmentation.
CUP indicates cancer of unknown primary; H-MSI, high microsatellite instability; IC, immune cell; MUP, melanoma of unknown primary site; NA, not available; NEC,
neuroendocrine carcinoma; NSCLC, non–small cell lung carcinoma; PD-L1, programmed death ligand 1; RCC, renal cell carcinoma; SCLC, small cell lung carcinoma; TC,
tumor cell; TMB, tumor mutational burden.
Percentile is defined as the value below which the listed percentage of TMB values fall, for that tumor type.
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and TSC2) were rare and affected single cases. Only 1,
unusual EGFR gene mutation (p.R776C) was detected in a
case of pulmonary adenocarcinoma.
CNAs were available for 13 carcinomas. Gains (≥ 6
copies) were observed in 12 genes including ADGRA2
(n= 2 cases), AKT2 (n= 2 cases), CCNDA, CCNE, FGF,
FGF3, FGF4, FGFR, MYB, NFIB, NSD3, and ZNF7
(n= 1 case each). Only 2 carcinomas harbored > 1 CNA:
ovarian serous adenocarcinoma (6 genes: ADGRA2,
CCNDA, FGF, FGF3, and FGF4) and lung squamous cell
carcinoma (4 genes: ADGRA2, AKT2, FGFR, and NSD3).
The Predictive Biomarkers in Metastatic
Melanomas
PD-L1 expression on melanoma TCs (> 1%) was
not observed in any of the tested cases (all TC negative).
However, PD-L1-positive ICs were detected in half of the
cases (n= 6/12).
High TMB was detected in 3/5 metastatic melano-
mas, including 2 MUP cases, with the average TMB of 9.6
mutations/Mbp. All tested cases were microsatellite stable.
BRAF mutations were detected in 8/12 metastatic
melanomas, including 6/8 MUP cases. NRAS mutation
was present in only 1 case (MUP). None of the melanoma
cases harbored GNAS gene mutations, although 1 case
harbored concurrent mutations in GNA11 and SF3B1. No
other detected molecular alterations were recurrent.
CNAs were available for 4 melanoma cases. Only 1
case (skin melanoma) harbored amplifications of the
CYP2D6 and EP3 genes.
DISCUSSION
Secondary (metastatic) cancers to the breast are rare
and contribute to ∼1% of all breast malignancies.1 Our
results on the frequency and types of secondary mammary
malignancies affecting the breast are in line with pre-
viously published data1,3 (Supplemental Table 1, Supple-
mental Digital Content 1, http://links.lww.com/AIMM/
A243). CUPs were rare (only 2 were present in our series),
whereas MUP site was more common.17–21 Our study
explored the biomarkers of targeted and I-O therapy in
this unique group of breast malignancies.
Among the metastatic carcinomas, a vast majority
(80%) originated from lung and reproductive tract/peri-
toneum. Half of the metastatic lung cancers were NEC.
These cancers may be clinically and histologically con-
fused for the primary mammary carcinomas with neuro-
endocrine differentiation.1 In contrast to the NEC of the
breast,10 metastatic NEC from the lung were uniformly
negative for steroid receptors ER, PR, and AR. In addi-
tion, these cancers lacked TC PD-L1 expression and
exhibited low TMB, as previously reported.22,23 However,
we confirm low (1% to 10%) IC PD-L1 in a proportion
of the metastatic pulmonary NECs, as reported by several
studies.23,24 Metastatic gynecologic/peritoneal carcin-
omas may also be confused for the primary mammary
malignancies, not only morphologically but immunohisto-
chemically, due to the frequent expression of steroid re-
ceptors, as confirmed in our study. None of these cases
harbored mutations in the ESR1 gene (encodes ER),
which may be seen in ∼20% of ER-positive breast cancers,
particularly in a metastatic setting.25–27 In addition,
HER2 protein expression was consistently negative among
the metastatic cancers to the breast, which is in contrast to
the primary breast cancers (frequency 15% to 20%). HER2
alterations (amplification and/or mutation) were also ab-
sent. HER2 mutations have been increasingly recognized
across the various cancers including breast (∼2% to 3%),
colorectal (∼1.5%), gastric/gastroesophageal junction
(∼1.5%), genitourinary (∼1%), gynecologic (∼1%), lung
(1%), and CUPs (∼1%).28–32 These mutations are asso-
ciated with the acquired resistance to HER2-targeted
therapies.33
Our data on I-O profile of metastatic gynecologic/
peritoneal carcinomas are in line with the previously
published data on their metastases to nonbreast sites.34,35
Thus, metastatic ovarian and fallopian tube/peritoneal
carcinomas were frequently enriched with PD-L1-positive
tumor-infiltrating lymphocytes, and a subset of these
harbored a high TMB. Such molecular alterations make
these cancers potentially amenable for the trials with im-
mune checkpoint inhibitors.
Three generations of EGFR tyrosine kinase in-
hibitors have been used for the treatment of NSCLC
TABLE 4. Overview of the Mutations Detected in Metastatic Cancers to the Breast
Histologic Subtype Mutations (n)
Carcinomas
Lung cancer
Non–small cell lung carcinoma TP53 (9), KRAS (3), PTEN (3), RB1 (2), AKT (1), FANCC (1), HRAS (1), ARID1A (1), ARID2 (1), EGFR (1)
Small cell lung carcinoma TP53 (2), RB1 (2), FBXW7 (1)
Ovarian cancer TP53 (7), BRAF (2), NRAS (1)
Fallopian tube/peritoneum TP53 (3), BRCA1 (1)
Kidney cancer VHL (2), SMARCB1 (1), PIK3CA (1)
Bladder cancer TP53 (2), PIK3CA (1)
Duodenum None
Colon cancer TP53 (1), NRAS (1)
Cancer of unknown primary KRAS (1), TP53 (1), KDM6A (1), TSC2 (1), STK1 (1)
Melanomas
Total BRAF (8), APC (1), CHEK1 (1), CTTNB1 (1), GNA11 (1), NRAS (1), PIK3CA (1), SF3B1 (1), TP53 (1)
Melanoma of unknown primary BRAF (6), APC (1), NRAS (1), PIK3CA (1), TP53 (1)
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harboring EGFR gene mutations.36,37 EGFR mutations
have been described in 14% to 23% NSCLCs among the
North American population.38 Activating EGFR gene
mutations are frequently detectable in metastatic
NSCLCs.39–42 A recent report of Ota et al43 confirmed the
presence of an activating EGFR gene mutation in a case of
metastatic pulmonary adenocarcinoma to the breast. In
addition, the author’s literature survey revealed EGFR
mutations in 4/4 tested intramammary metastases of
pulmonary adenocarcinomas.43 In our study, a rare
pathogenic EGFR mutation was detected in 1 case
(pulmonary adenocarcinoma). The detected mutation (p.
R776C) affects the protein kinase domain of the EGFR,
resulting in its constitutive phosphorylation.44,45 The
presence of such a mutation may also have therapeutic
implications given that it may decrease the sensitivity to
gefitinib and increase the sensitivity to erlotinib and
AEE788.46 The remaining metastatic NSCLCs in our
study were devoid of EGFR gene alterations; hence, these
cancers may not be suitable for treatment with EGFR
tyrosine kinase inhibitors.
We had 2 CUP cases in our cohort, 1 with squamous
and another with adenocarcinoma differentiation. The
case presenting with squamous differentiation had a high
TMB and high PD-L1 expression, making the patient
potentially amenable to the treatment with immune
checkpoint inhibitors.7 The other case of CUP harbored
concurrent KRAS (p.G12V) and STK11 (p. D194N) gene
mutations. Germline STK mutations have been described
in patients with Peutz-Jeghers syndrome (OMIM #
175200), whereas somatic STK11 mutations have been
reported in a wide spectrum of malignancies including
lung, cervical, pancreatic, testicular, and other
cancers.47,48 In the context of activating KRAS mutations,
mutations leading to a loss of STK11 function have been
associated with decreased response to immune checkpoint
inhibitors.49
The molecular profile of metastatic melanomas to
the breast (PD-L1 and TMB status) are concordant with
the previous studies on cutaneous melanoma, including
MUP cases.50–54
It is well known that BRAF-mutant melanomas are
prone to exhibit more aggressive biological behavior than
BRAF wild-type melanomas.55 We found pathogenic
BRAF mutations in two thirds of metastatic melanomas,
which is comparable to previous studies (∼50%).55–57 One
case harbored concurrent mutations in GNA11 (p. Q209L)
and SF3B1 (p. R625C). Although these mutations are
mostly associated with uveal melanoma, they have also
been reported in skin and mucosal melanomas.58,59 In an
analysis of publically available genomic databases
(TCGA), no GNA11Q209 mutations were detected outside
of melanoma. SF3B1R625 mutations were enriched in
nonuveal melanomas compared with other “hotspot”
mutations; however, SF3B1 mutations in previously de-
termined “hotspots” were also identified in primary breast
carcinoma (1.1% of samples with the highest incidence of
p.K700E). Melanomas of cutaneous origin that harbor
these mutations have been associated with lower TMB
and a lack of response to immunotherapies.60 This is,
however, not fully consistent with our findings given that
the specimen had a high TMB (13 mutations/Mbp), al-
though no PD-L1 expression on either TC or IC compo-
nents was observed.
In a small proportion of metastatic cancers to the
breast, we detected a lineage-characteristic mutation that
may improve the diagnosis (eg, VHL in renal clear cell
carcinomas, SMARCB1 in renal medullary carcinomas)
and/or have therapeutic implications (BRCA1 and
BRAF). Thus, BRCA1 mutations in fallopian tube carci-
nomas and BRAF mutations in melanomas may guide
targeted treatments with poly (ADP-ribose) polymerase,
and BRAF and MEK inhibitors.
In conclusion, we confirm the rarity of secondary
cancers to the breast (1.4% of all breast biopsies with a
malignancy). Their histotype distribution is in line with
previous studies.1,3 Metastatic cancers to the breast shared
similar molecular profile to their primary counterparts.
The study also revealed a marked heterogeneity in terms
of biomarkers of potential benefit to I-O and targeted
therapies, necessitating individual patient profiling. The
clinical impact of the targetable biomarkers in secondary
cancers to the breast has to be determined.
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